

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA
SAN FRANCISCO DIVISION

PLUMBERS & PIPEFITTERS LOCAL)	Case No. 3:22-cv-03023-TLT (Securities Case)
UNION #295 PENSION FUND, Individually and)	
on Behalf of All Others Similarly Situated,)	<u>CLASS ACTION</u>
)	
Plaintiff,)	NOTICE OF: (i) PENDENCY OF CLASS
)	ACTION, CERTIFICATION OF CLASS, AND
vs.)	PROPOSED SETTLEMENT AND PLAN OF
)	ALLOCATION; (ii) SETTLEMENT FAIRNESS
CAREDX, INC., et al.,)	HEARING; AND (iii) MOTION FOR AN
)	AWARD OF ATTORNEYS' FEES AND
Defendants.)	LITIGATION EXPENSES
)	

A Federal Court Authorized This Notice. This Is Not a Solicitation from a Lawyer.

NOTICE OF PENDENCY OF CLASS ACTION: Please be advised that your rights may be affected by the above-captioned class action lawsuit pending in this Court (the “Action”) if you purchased common stock of CareDx, Inc. (“CareDx” or the “Company”) between May 1, 2020 and November 3, 2022, inclusive (the “Class Period”).

NOTICE OF SETTLEMENT: Please also be advised that lead plaintiffs Oklahoma Police Pension and Retirement System, Sheet Metal Workers Local 19 Pension Fund, Local 353, I.B.E.W. Pension Fund, and Beaumont Firemen’s Relief & Retirement Fund (“Lead Plaintiffs”), on behalf of the Class (as defined in ¶1 below), have reached a proposed settlement of the Action for a total of \$20.25 million in cash that will resolve all claims in the Action (the “Settlement”).

This Notice explains important rights you may have, including your possible receipt of cash from the Settlement. Your legal rights will be affected whether or not you act. Please read this Notice carefully. If you are a broker or custodian, please immediately review this Notice for instructions on providing timely notification to beneficial owners.

1. **Description of the Action and the Class:** This Notice relates to a proposed Settlement of a class action lawsuit pending against the following defendants: CareDx, Inc., Peter Maag, and Reginald Seeto (“Defendants”) (collectively, with Lead Plaintiffs, the “Settling Parties” or “Parties”). The proposed Settlement, if approved by the Court, will apply to the following Class (the “Class”): all persons or entities who purchased CareDx, Inc. common stock between May 1, 2020 and November 3, 2022, inclusive, and were damaged thereby. Excluded from the Class are Defendants, the officers and directors of the Company, at all relevant times, members of their immediate families, and their legal representatives, heirs, successors, or assigns, and any entity in which Defendants have or had a controlling interest. Also excluded from the Class are those persons and entities who timely and validly request exclusion from the Class pursuant to this Notice.¹

2. **Statement of Class Recovery:** Subject to Court approval, and as described more fully in ¶¶3-6 below, Lead Plaintiffs, on behalf of the Class, have agreed to settle all Released Claims (as defined in ¶53 below) against Defendants and other Released Defendants Parties (as defined in ¶55 below) in exchange for a settlement payment of \$20.25 million in cash (the “Settlement Amount”) to be deposited into an escrow account. The Net Settlement Fund (the Settlement Fund less Taxes and Tax Expenses, Notice and Administration Costs, and attorneys’ fees and litigation expenses) will be distributed in accordance with a plan of allocation (the “Plan of Allocation”) that will be approved by the Court and will determine how the Net Settlement Fund shall be distributed to members of the Class. The Plan of Allocation is a basis for determining the relative positions of Class Members for purposes of allocating the Net Settlement Fund. The proposed Plan

¹ All capitalized terms used in this Notice that are not otherwise defined herein shall have the meanings provided in the Stipulation of Settlement dated May 16, 2025 (“Stipulation”), which is available on the website www.CareDxSecuritiesLitigation.com.

of Allocation is included in this Notice, and may be modified by the Court without further notice.

3. **Statement of Average Distribution Per Share:** The Settlement Fund consists of the \$20.25 million Settlement Amount plus interest earned. Assuming all potential Class Members elect to participate, the estimated average recovery is \$0.32 per damaged share before fees and expenses. Class Members may recover more or less than this amount depending on, among other factors, the aggregate value of the Recognized Claims represented by valid and acceptable Proof of Claim and Release Forms (the “Claim Form” or “Proof of Claim”) as explained in the Plan of Allocation; when their shares were purchased and the price at the time of purchase; and whether the shares were sold, and if so, when they were sold and for how much. In addition, the actual recovery of Class Members may be further reduced by the payment of fees and expenses from the Settlement Fund, as approved by the Court.

4. **Statement of the Parties’ Position on Damages:** Defendants deny all claims of wrongdoing, that they engaged in any wrongdoing, that they are liable to Lead Plaintiffs and/or the Class, and that Lead Plaintiffs or other members of the Class suffered any injury. Moreover, the Parties do not agree on the amount of recoverable damages if Lead Plaintiffs were to prevail on each of the claims. The issues on which the Parties disagree include, but are not limited to, whether: (i) the statements made or facts allegedly omitted were material, false, or misleading; (ii) Defendants are otherwise liable under the securities laws for those statements or omissions; and (iii) all or part of the damages allegedly suffered by members of the Class were caused by economic conditions or factors other than the allegedly false or misleading statements or omissions.

5. **Statement of Attorneys’ Fees and Expenses Sought:** Lead Counsel will apply to the Court for an award of attorneys’ fees from the Settlement Fund of no more than 30% of the Settlement Amount, plus interest earned at the same rate and for the same period as earned by the Settlement Fund. In addition, Lead Counsel also will apply to the Court for payment from the Settlement Fund for Lead Counsel’s litigation expenses (reasonable expenses or charges of Lead Counsel in connection with commencing and prosecuting the Action), in a total amount not to exceed \$450,000, plus interest earned at the same rate and for the same period as earned by the Settlement Fund. If the Court approves Lead Counsel’s fee and expense application, the estimated average cost per damaged share is \$0.10. In addition, Lead Plaintiffs may each seek an award in an amount not to exceed \$7,500, pursuant to 15 U.S.C. §78u-4(a)(4) in connection with their representation of the Class.

6. **Identification of Attorneys’ Representatives:** Lead Plaintiffs and the Class are represented by Robbins Geller Rudman & Dowd LLP and Saxena White P.A. (“Lead Counsel”): Jason C. Davis at Robbins Geller Rudman & Dowd LLP, Post Montgomery Center, One Montgomery Street, Suite 1800, San Francisco, CA 94104, 1-800-449-4900, settlementinfo@rgrdlaw.com and Lester R. Hooker at Saxena White P.A., 7777 Glades Road, Suite 300, Boca Raton, FL 33434, lhooke@saxenawhite.com.

YOUR LEGAL RIGHTS AND OPTIONS IN THIS SETTLEMENT	
DO NOTHING	Get no payment. Remain a Class Member. Give up your rights.
REMAIN A MEMBER OF THE CLASS AND SUBMIT A CLAIM FORM RECEIVED² OR SUBMITTED ONLINE NO LATER THAN NOVEMBER 12, 2025	This is the only way to be potentially eligible to receive a payment. If you wish to obtain a payment as a member of the Class, you will need to file a claim form (the “Claim Form” or “Proof of Claim Form”), received no later than November 12, 2025.
EXCLUDE YOURSELF FROM THE CLASS BY SUBMITTING A REQUEST FOR EXCLUSION THAT IS RECEIVED NO LATER THAN OCTOBER 14, 2025	Get no payment. This is the only option that potentially allows you to ever be part of any other lawsuit against the Defendants or any other Released Defendants Parties about the legal claims being resolved by this Settlement. You cannot object to the proposed Settlement and cannot submit a Claim Form if you exclude yourself.
OBJECT TO THE SETTLEMENT SO THAT IT IS FILED OR RECEIVED NO LATER THAN OCTOBER 14, 2025	If you do not like the proposed Settlement, the proposed Plan of Allocation, or the request for attorneys’ fees and litigation expenses, you may write to the Court and explain why you do not like them. You cannot object to the Settlement, the Plan of Allocation, or the fee and expense request unless you are a Class Member and do not exclude yourself from the Class. You do not need to submit a Claim Form to object. However, if you object, you must still submit a Claim Form in order to be potentially eligible to receive any money from the Net Settlement Fund. If you submit a written objection, you may (but do not have to) attend the hearing.
GO TO THE HEARING ON DECEMBER 2, 2025, AT 2:00 P.M., AND FILE A NOTICE OF INTENTION TO APPEAR SO THAT IT IS RECEIVED NO LATER THAN OCTOBER 14, 2025	Ask to speak in Court about the fairness of the Settlement, the proposed Plan of Allocation, or the request for attorneys’ fees and litigation expenses.

² Claims, objections, requests for exclusion, and other correspondence that are legibly postmarked will be treated as received on the postmark date. Please be advised that the U.S. Postal Service may not postmark mail which is not presented in person.

WHAT THIS NOTICE CONTAINS

What Is The Purpose of This Notice?	Page 4
What Is This Case About? What Has Happened So Far?	Page 5
How Do I Know If I Am Affected By The Settlement?	Page 6
What Are Lead Plaintiffs' Reasons For The Settlement?	Page 6
What Might Happen If There Were No Settlement?	Page 7
How Much Will My Payment Be?	Page 7
Plan of Allocation	Page 7
How are Class Members Affected by the Action and the Settlement?	Page 12
What Payment are the Attorneys for the Class Seeking? How Will the Lawyers be Paid?	Page 13
How Do I Participate in the Settlement? What Do I Need to Do?	Page 13
What if I Do Not Want to be a Member of the Class? How Do I Exclude Myself?	Page 13
When And Where Will The Court Decide Whether To Approve The Settlement? Do I Have To Come To The Hearing?	Page 14
May I Speak At The Hearing If I Do Not Like The Settlement?	
What If I Bought Shares On Someone Else's Behalf?	Page 15
Can I See The Court File? Whom Should I Contact If I Have Questions?	Page 16

WHAT IS THE PURPOSE OF THIS NOTICE?

7. The purpose of this Notice is to inform you about: (i) this Action; (ii) the terms of the proposed Settlement; and (iii) your rights in connection with a hearing to be held before the United States District Court for the Northern District of California (the "Court"), on December 2, 2025, at 2:00 p.m., to consider the fairness, reasonableness, and adequacy of the Settlement and related matters. This Notice also describes the steps to be taken by those who wish to seek to be potentially eligible to share in the distribution of the Net Settlement Fund in the event the Settlement is approved by the Court.

8. A class action is a type of lawsuit in which the claims of a number of individuals are resolved together, thus providing the class members with both consistency and efficiency. In a class action lawsuit, one or more people, known as class representatives, sue on behalf of people who have similar claims. All of the people with similar claims are referred to as a Class or Class Members. One court resolves the issues for all Class Members, except for those Class Members who exclude themselves from the Class. In this Action, the Court has preliminarily certified the Class for settlement purposes and appointed Lead Plaintiffs Oklahoma Police Pension and Retirement System, Sheet Metal Workers Local 19 Pension Fund, Local 353, I.B.E.W. Pension Fund, and Beaumont Firemen's Relief & Retirement Fund as the representatives of the Class and Lead Counsel as Class Counsel.

9. The Court in charge of this case is the United States District Court for the Northern District of California, and the case is known as *Plumbers & Pipefitters Local Union #295 Pension Fund v. CareDx, Inc., et al.*, No. 3:22-cv-03023-TLT (N.D. Cal.). The judge presiding over this case is the Honorable Trina L. Thompson, United States District Judge. The entities who are suing are called Lead Plaintiffs, and those who are being sued are called defendants. In this case, the Defendants are CareDx, Peter Maag, and Reginald Seeto.

10. This Notice explains the lawsuit, the Settlement, your legal rights, what benefits are available, who is eligible for them, and how to get them. The purpose of this Notice is to inform you of this case, that it is a class action, and how you might be affected. It also informs you of the terms of the proposed Settlement, and of a hearing to be held by the Court to consider the fairness, reasonableness, and adequacy of the proposed Settlement, the proposed Plan of Allocation, and the application by Lead Counsel for attorneys' fees and litigation expenses (the "Settlement Hearing").

11. The Settlement Hearing will be held on December 2, 2025, at 2:00 p.m., before the Honorable Trina L. Thompson, at the United States District Court, Northern District of California, Philip Burton Federal Building & United States Courthouse, Courtroom 9 – 19th Floor, 450 Golden Gate Avenue, San Francisco, CA 94102, for the following purposes:

- (a) to determine whether the Class should finally be certified pursuant to Rule 23;
- (b) to determine whether the proposed Settlement on the terms and conditions provided for in the Stipulation is fair, reasonable, and adequate and should be approved by the Court;
- (c) to determine whether the Judgment as provided for under the Stipulation should be entered;
- (d) to determine whether the proposed Plan of Allocation for the net proceeds of the Settlement is fair and reasonable and should be approved by the Court;
- (e) to determine whether the application by Lead Counsel for an award of attorneys' fees and litigation expenses and awards to Lead Plaintiffs should be approved; and
- (f) to rule upon such other matters as the Court may deem appropriate.

12. This Notice does not express any opinion by the Court concerning the merits of any claim in the Action, and the Court still has to decide whether to approve the Settlement. If the Court approves the Settlement, payments to Authorized Claimants will be made after any appeals are resolved, and after the completion of all claims processing. This process takes time. Please be patient.

WHAT IS THIS CASE ABOUT? WHAT HAS HAPPENED SO FAR?

13. Lead Plaintiffs allege that during the period between April 30, 2020 and November 3, 2022, Defendants purportedly made materially false or misleading statements in violation of §10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 promulgated thereunder, which caused the price of CareDx common stock to trade at allegedly inflated prices. Specifically, Lead Plaintiffs allege that Defendants purportedly made material misrepresentations and omissions, with scienter, in connection with the Company's compliance-with-law statements and statements about testing services revenue and historical RemoTraC data. Lead Plaintiffs allege that persons who purchased CareDx common stock during the Class Period allegedly suffered economic losses when the price of CareDx common stock declined after the Company reported declining testing revenue, among other things, on certain dates in 2021 and 2022. Defendants have denied and continue to deny each and all of the claims alleged by Lead Plaintiffs in the Action and have denied and continued to deny that they engaged in any wrongdoing whatsoever or that persons who purchased CareDx common stock during the relevant time period suffered any economic losses as a result of any purported wrongdoing by Defendants.

14. The original securities class action complaint in the Action was filed in this District on May 23, 2022. ECF 1. Plaintiffs then moved for an order appointing them as Lead Plaintiffs in the case and approving their selection of lead counsel for the Class. ECF 31. The Court subsequently granted Plaintiffs' motion and appointed Plaintiffs as Lead Plaintiffs for the case and the firms of Robbins Geller Rudman & Dowd LLP and Saxena White P.A. as Lead Counsel. ECF 43.

15. On November 28, 2022, Plaintiffs filed their first amended complaint ("FAC"). ECF 53. Defendants moved to dismiss and to strike portions of the FAC. ECF 58, 60. The Court struck some paragraphs from the FAC and dismissed the FAC entirely, with leave to amend. ECF 75.

16. On June 28, 2023, Plaintiffs filed their second amended complaint ("SAC"). ECF 81. Defendants again moved to dismiss and to strike portions of the SAC. ECF 89, 91. The Court again struck certain paragraphs from the SAC and dismissed the SAC entirely, with leave to amend. ECF 123. However, the Court found that for their Section 10(b) and Rule 10b-5 claim, Plaintiffs had sufficiently alleged falsity as to statements regarding underwriting representations and statements regarding testing services revenue and historical RemoTraC data. *Id.* at 43. The Court also found that Plaintiffs had sufficiently alleged loss causation. *Id.*

17. On November 1, 2024, Plaintiffs filed their corrected third amended complaint ("TAC"). ECF 133. Plaintiffs allege that Defendants CareDx, Dr. Maag, and Dr. Seeto violated: (1) Section 10(b) of the Exchange Act and Rule 10b-5 promulgated thereunder; and (2) Section 20(a) of the Exchange Act. *Id.*, ¶¶367-380. Defendants subsequently moved to dismiss the TAC. ECF 136. Plaintiffs timely filed an opposition, and Defendants timely filed a reply. ECF 138, 144. The Court heard oral argument on January 28, 2025. ECF 150. On February 18, 2025, the Court denied Defendants' motion to dismiss the TAC. ECF 154.

18. The Parties thereafter exchanged Initial Disclosures pursuant to Fed. R. Civ. P. 26 and began formal fact discovery and negotiations regarding an ESI Protocol and Protective Order. Plaintiffs served two sets of Requests for Production of Documents, Interrogatories and several deposition subpoenas and notices, and Defendants served Interrogatories, Requests for Production of Documents and notices for the depositions of all Plaintiffs. During this time,

Defendants produced over 2.4 million pages of documents to Plaintiffs in response to Plaintiffs' First Requests for Production. Plaintiffs commenced reviewing and analyzing those materials.

19. During the course of the Action, the Parties engaged a neutral, third-party mediator, the Hon. Gary A. Feess (Ret.), to aid in settlement negotiations. Judge Feess has extensive experience mediating complex class action litigations such as this Action. The Parties engaged in an in-person mediation session and numerous teleconferences with Judge Feess in an effort to resolve the Action throughout April 2025. The Parties also exchanged mediation briefs ahead of their in-person mediation session, setting forth their respective arguments concerning liability and damages and respective views of the merits of the Action. Though the Parties' initial mediation session on April 1, 2025 was unsuccessful in resolving the case, the Parties continued to have telephonic and email exchanges with Judge Feess regarding a potential resolution.

20. On April 21, 2025, Judge Feess issued a mediator's proposal to resolve the Action for \$20,250,000, which the Settling Parties accepted as an agreement in principle.

21. On July 23, 2025, the Court preliminarily approved the Settlement, authorized this Notice to be disseminated to potential Class Members, provisionally certified the Class, and scheduled the Settlement Hearing to consider, among other things, whether to grant final approval of the Settlement.

HOW DO I KNOW IF I AM AFFECTED BY THE SETTLEMENT?

22. If you are a member of the Class, you are subject to the Settlement unless you timely request to be excluded. The Class consists of all persons or entities who purchased CareDx, Inc. common stock between May 1, 2020 and November 3, 2022, inclusive, and were damaged thereby. Excluded from the Class are Defendants, the officers and directors of the Company, at all relevant times, members of their immediate families, and their legal representatives, heirs, successors, or assigns, and any entity in which Defendants have or had a controlling interest. Also excluded from the Class are those persons and entities who timely and validly request exclusion from the Class pursuant to this Notice.

RECEIPT OF THIS NOTICE OR POSTCARD NOTICE DOES NOT NECESSARILY MEAN THAT YOU ARE A CLASS MEMBER OR THAT YOU ARE ENTITLED TO RECEIVE PROCEEDS FROM THE SETTLEMENT. IF YOU WISH TO BE POTENTIALLY ELIGIBLE TO RECEIVE A DISTRIBUTION OF THE SETTLEMENT PROCEEDS, YOU MUST COMPLETE, SIGN, AND SUBMIT THE CLAIM FORM TO BE RECEIVED NO LATER THAN NOVEMBER 12, 2025. YOU MAY ALSO SUBMIT A CLAIM FORM ONLINE AT WWW.CAREDXSECURITIESLITIGATION.COM BY NOVEMBER 12, 2025.

WHAT ARE LEAD PLAINTIFFS' REASONS FOR THE SETTLEMENT?

23. Lead Plaintiffs and Lead Counsel believe that the claims asserted against Defendants have merit. Lead Plaintiffs and Lead Counsel recognize, however, the expense and length of continued proceedings necessary to pursue their claims against Defendants through trial and appeals, as well as the difficulties in establishing liability and damages. Lead Plaintiffs and Lead Counsel have considered the amount of the Settlement, as well as the uncertain outcome and risk in complex lawsuits like this one. Such risks include, in particular, the risk that the anticipated motion(s) for summary judgment and challenges to Lead Plaintiffs' experts could be granted and the risk, among others, that Lead Plaintiffs could be unsuccessful in proving that Defendants' alleged misstatements were materially false and misleading, made with scienter (that is, the requisite state of mind), or caused compensable damages to the Class.

24. In light of the amount of the Settlement and the immediacy of recovery to the Class, Lead Plaintiffs and Lead Counsel believe that the proposed Settlement is fair, reasonable, and adequate, and in the best interests of the Class. Lead Plaintiffs and Lead Counsel believe that the Settlement provides a substantial benefit now, namely \$20.25 million in cash (less the various deductions described in this Notice), as compared to the risk that the claims would produce a smaller recovery, or no recovery after resolution of Plaintiffs' motion for class certification, Defendants' anticipated summary judgment motion(s), trial and appeals, possibly years in the future. Moreover, Lead Plaintiffs and Lead Counsel considered CareDx's current financial condition and limited available resources to fund a settlement, including CareDx's finite available D&O insurance policies. Further litigation, given its likely length and intensity, would have rapidly depleted these insurance policies and Lead Plaintiffs and Lead Counsel believe there was a very real risk (if not a virtual certainty) that the Class would have recovered less than the \$20.25 million settlement amount, or nothing at all.

25. Defendants have denied and continue to deny each and all of the claims alleged by Lead Plaintiffs in the Action. Defendants expressly have denied and continue to deny all charges of wrongdoing or liability against them arising

out of any of the conduct, statements, acts or omissions alleged, or that could have been alleged, in the Action. Defendants also have denied and continue to deny, among other things, the allegations that Lead Plaintiffs or the Class have suffered any damage, and that Lead Plaintiffs or the Class were harmed by the conduct alleged in the Action.

WHAT MIGHT HAPPEN IF THERE WERE NO SETTLEMENT?

26. If there were no Settlement and Lead Plaintiffs failed to establish any essential legal or factual element of the alleged claims, neither Lead Plaintiffs nor the Class would recover anything from Defendants. Also, if Defendants were successful in proving any of their defenses, the Class likely would recover substantially less than the amount provided in the Settlement, or nothing at all. Furthermore, even if Lead Plaintiffs successfully continued litigation (including at summary judgment, at trial, or on appeal), given CareDx's limited available resources to fund any such recovery, there was a significant risk that the Action would produce a smaller, or no, recovery.

HOW MUCH WILL MY PAYMENT BE?

27. Defendants have agreed to cause to be paid \$20,250,000.00 in cash into escrow for the benefit of the Class. At this time, it is not possible to make any determination as to how much individual Class Members may receive from the Settlement. Lead Plaintiffs have proposed a plan for allocating the Net Settlement Fund to those Class Members who timely submit valid Proofs of Claim. The Plan of Allocation proposed by Lead Plaintiffs is set forth below, and additional information is available on the case-specific website, www.CareDxSecuritiesLitigation.com.

28. The Court has reserved jurisdiction to allow, disallow, or adjust on equitable grounds the claim of any member of the Class.

29. The Plan of Allocation set forth below is the proposed plan submitted by Lead Plaintiffs and Lead Counsel for the Court's approval. The Court may approve this plan as proposed or it may modify it without further notice to the Class.

30. Each claimant shall be deemed to have submitted to the jurisdiction of the United States District Court for the Northern District of California, with respect to their, his, her, or its Claim Form.

31. Persons and entities that request to exclude themselves from the Class will not be eligible to receive a distribution from the Net Settlement Fund and shall not submit a Claim Form.

PLAN OF ALLOCATION

32. The Settlement Amount of \$20.25 million and any interest earned thereon shall be the "Settlement Fund." The Settlement Fund, less all taxes, tax expenses, notice and administration expenses, approved attorneys' fees and expenses, and any other fees or expenses approved by the Court is the "Net Settlement Fund." The Net Settlement Fund shall be distributed to Class Members who submit timely and valid Proofs of Claim to the Claims Administrator ("Authorized Claimants").

33. The Plan of Allocation set forth herein is the plan that is being proposed by Lead Plaintiffs and their counsel to the Court for approval. The Court may approve this Plan of Allocation or modify it without additional notice to the Class. Any order modifying the Plan of Allocation will be posted on the Settlement website at: www.CareDxSecuritiesLitigation.com.

34. The objective of the Plan of Allocation is to equitably distribute the Net Settlement Fund among Authorized Claimants who suffered economic losses as a proximate result of the alleged wrongdoing. The calculations made pursuant to the Plan of Allocation are not intended to be estimates of, nor indicative of, the amounts that Class Members might have been able to recover after a trial. Nor are the calculations pursuant to the Plan of Allocation intended to be estimates of the amounts that will be paid to Authorized Claimants pursuant to the Settlement. The computations under the Plan of Allocation are only a method to weigh the claims of Authorized Claimants against one another for the purposes of making *pro rata* allocations of the Net Settlement Fund.

35. The Plan of Allocation was created with the assistance of a consulting damages expert and reflects the assumption that Defendants' alleged false and misleading statements and material omissions proximately caused the price of CareDx common stock to be artificially inflated throughout the Class Period. In calculating the estimated artificial

inflation allegedly caused by Defendants' alleged misrepresentations and omissions, Lead Plaintiffs' damages expert considered price changes in CareDx common stock in reaction to certain public announcements allegedly revealing the truth concerning Defendants' alleged misrepresentations and material omissions, adjusting for price changes that were attributable to market or industry forces.

36. In order to have recoverable damages, the disclosure of the allegedly misrepresented information must be the cause of the decline in the price of CareDx common stock. In this case, Lead Plaintiffs allege that Defendants made false statements and omitted material facts during the period between April 30, 2020 through November 3, 2022, which had the effect of artificially inflating the price of CareDx common stock. Lead Plaintiffs further allege that relevant information was released to the market on October 28, 2021 (after market close), January 10, 2022 (before market open), May 5, 2022 (after market close), May 23, 2022 (before market open), September 1, 2022 (after market close), and November 3, 2022 (after market close), which removed the artificial inflation from the price of CareDx common stock on October 29, 2021, May 6, 2022, May 23, 2022, September 2, 2022, and November 4, 2022, while also causing artificial inflation to increase on January 10, 2022.

37. Recognized Loss Amounts are based primarily on the difference in the amount of alleged artificial inflation in the prices of CareDx common stock at the time of purchase or acquisition and at the time of sale, or the difference between the actual purchase price and sale price. Accordingly, in order to have a Recognized Loss under the Plan of Allocation, a Class Member who or which purchased or otherwise acquired CareDx common stock during the Class Period must have held those shares through at least October 29, 2021.

CALCULATION OF RECOGNIZED LOSS AMOUNTS

38. Based on the formula stated below, a "Recognized Loss Amount" will be calculated for each purchase or acquisition of publicly traded CareDx common stock made in the United States that is listed on the Claim Form and for which adequate documentation is provided. If a Recognized Loss Amount calculates to a negative number or zero under the formula below, that number will be zero.

39. For each share of publicly traded CareDx common stock purchased or otherwise acquired in the United States during the Class Period (*i.e.*, during the period from May 1, 2020 through and including the close of trading on November 3, 2022), and:

- i. sold before October 29, 2021, the Recognized Loss Amount will be \$0.00.
- ii. sold from October 29, 2021 through the close of trading on November 3, 2022, the Recognized Loss Amount will be ***the least of***: (i) the amount of artificial inflation per share on the date of purchase/acquisition, as shown in Table A below minus the amount of artificial inflation per share on the date of sale as shown in Table A below; (ii) the purchase/acquisition price minus the sale price.
- iii. sold from November 4, 2022 through and including the close of trading on February 1, 2023, the Recognized Loss Amount will be ***the least of***: (i) the amount of artificial inflation per share on the date of purchase/acquisition, as shown in Table A below; (ii) the purchase/acquisition price minus the average closing price between November 4, 2022 and the date of sale as stated in Table B below; or (iii) the purchase/acquisition price minus the sale price.
- iv. held as of the close of trading on February 1, 2023, the Recognized Loss Amount will be ***the lesser of***: (i) the amount of artificial inflation per share on the date of purchase/acquisition as shown in Table A; or (ii) the purchase/acquisition price minus \$13.21.³

³ Pursuant to Section 21D(e)(1) of the Exchange Act, "in any private action arising under this title in which the plaintiff seeks to establish damages by reference to the market price of a security, the award of damages to the plaintiff shall not exceed the difference between the purchase or sale price paid or received, as appropriate, by the plaintiff for the subject security and the mean trading price of that security during the 90-day period beginning on the date on which the information correcting the misstatement or omission that is the basis for the action is disseminated to the market." Consistent with the requirements of the Exchange Act, Recognized Loss Amounts are reduced to an appropriate extent by taking into account the closing prices of CareDx common stock during the "90-day look-back period," November 4, 2022 through and including February 1, 2023. The mean (average) closing price for CareDx common stock during this 90-day look-back period was \$13.21.

ADDITIONAL PROVISIONS

40. **Calculation of Claimant's "Recognized Claim":** A Claimant's "Recognized Claim" will be the sum of his, her, or its Recognized Loss Amounts as calculated above with respect to CareDx common stock.

41. **FIFO Matching:** If a Class Member made more than one purchase/acquisition or sale of CareDx common stock during the Class Period, all purchases/acquisitions and sales will be matched on a First In, First Out ("FIFO") basis. Class Period sales will be matched first against any holdings at the beginning of the Class Period, and then against purchases/acquisitions in chronological order, beginning with the earliest purchase/acquisition made during the Class Period.

42. **"Purchase/Sale" Dates:** Purchases or acquisitions and sales of CareDx common stock will be deemed to have occurred on the "contract" or "trade" date as opposed to the "settlement" or "payment" date. The receipt or grant by gift, inheritance, or operation of law of CareDx common stock during the Class Period shall not be deemed a purchase, acquisition or sale of CareDx common stock for the calculation of a claimant's Recognized Loss Amount, nor shall the receipt or grant be deemed an assignment of any claim relating to the purchase/acquisition/sale of CareDx common stock unless (i) the donor or decedent purchased or otherwise acquired or sold CareDx common stock during the Class Period; (ii) the instrument of gift or assignment specifically provides that it is intended to transfer such rights; and (iii) no Claim was submitted by or on behalf of the donor, on behalf of the decedent, or by anyone else with respect to such shares of CareDx common stock.

43. **Short Sales:** The date of covering a "short sale" is deemed to be the date of purchase or acquisition of the CareDx common stock. The date of a "short sale" is deemed to be the date of sale of the CareDx common stock. In accordance with the Plan of Allocation, however, the Recognized Loss Amount on "short sales" and the purchases covering "short sales" is zero.

44. In the event that a claimant has an opening short position in CareDx common stock, the earliest purchases or acquisitions of CareDx common stock during the Class Period will be matched against such opening short position and not be entitled to a recovery until that short position is fully covered.

45. **Common Stock Purchased/Sold Through the Exercise of Options:** With respect to CareDx common stock purchased or sold through the exercise of an option, the purchase/sale date of the common stock is the exercise date of the option and the purchase/sale price is the exercise price of the option.

46. **Determination of Distribution Amount:** If the sum total of Recognized Claims of all Authorized Claimants who are entitled to receive payment out of the Net Settlement Fund is greater than the Net Settlement Fund, each Authorized Claimant shall receive his, her, or its *pro rata* share of the Net Settlement Fund. The *pro rata* share will be the Authorized Claimant's Recognized Claim divided by the total of Recognized Claims of all Authorized Claimants, multiplied by the total amount in the Net Settlement Fund.

47. If the Net Settlement Fund exceeds the sum total amount of the Recognized Claims of all Authorized Claimants entitled to receive payment out of the Net Settlement Fund, the excess amount in the Net Settlement Fund will be distributed *pro rata* to all Authorized Claimants entitled to receive payment.

48. If an Authorized Claimant's Distribution Amount calculates to less than \$10.00, no distribution will be made to that Authorized Claimant.

49. After the initial distribution of the Net Settlement Fund, the Claims Administrator will make reasonable and diligent efforts to have Authorized Claimants cash their distribution checks. If there is any balance remaining in the Net Settlement Fund after a reasonable amount of time following the date of the initial distribution of the Net Settlement Fund, Lead Counsel shall, if feasible, reallocate such balance among Authorized Claimants who negotiated the checks sent to them in the initial distribution and who would receive at least \$10.00 in an equitable and economical fashion. These reallocations shall be repeated until the balance remaining in the Net Settlement Fund is *de minimis* and such remaining balance shall then be donated to the Council of Institutional Investors.

50. Payment pursuant to the Plan of Allocation, or such other plan of allocation as may be approved by the Court, will be conclusive against all Authorized Claimants. No person shall have any claim against Lead Plaintiffs, Lead Counsel, Lead Plaintiffs' damages expert, Lead Plaintiffs' consulting experts, Defendants, Defendants' Counsel, or any of the other Released Parties, or the Claims Administrator or other agent designated by Lead Counsel arising from distributions made substantially in accordance with the Stipulation, the plan of allocation approved by the Court, or further Orders of the Court. Lead Plaintiffs, the Defendants and their respective counsel, and all other Released Defendants Parties, shall have no responsibility or liability whatsoever for the investment or distribution of the Settlement Fund or the Net Settlement

Fund, the Plan of Allocation, the determination, administration, calculation, or payment of any Claim or nonperformance of the Claims Administrator, the payment or withholding of Taxes, or any losses incurred in connection therewith.

51. The Plan of Allocation stated herein is the plan that is being proposed to the Court for its approval by Lead Plaintiffs after consultation with their damages expert. The Court may approve this plan as proposed or it may modify the Plan of Allocation without further notice to the Class. Any Orders regarding any modification of the Plan of Allocation will be posted on the case website, www.CareDxSecuritiesLitigation.com.

TABLE A

**Estimated Artificial Inflation with Respect to CareDx Common Stock Transactions
May 1, 2020 Through and Including November 3, 2022**

Date Range of Transaction	Artificial Inflation Per Share
5/1/2020 - 10/28/2021	\$19.65
10/29/2021 - 1/9/2022	\$0.42
1/10/2022 - 5/5/2022	\$7.42
5/6/2022 - 5/22/2022	\$5.57
5/23/2022 - 9/1/2022	\$3.08
9/2/2022 - 11/3/2022	\$1.81
11/4/2022 - Present	\$0.00

TABLE B
90-Day Look-back Table for CareDx Common Stock
Closing Price and Average Closing Price
November 4, 2022 through February 1, 2023

Date	Closing Price	Average Closing Price Between November 04, 2022 and Date Shown	Date	Closing Price	Average Closing Price Between November 04, 2022 and Date Shown
11/4/2022	\$16.02	\$16.02	12/19/2022	\$11.54	\$13.33
11/7/2022	\$15.86	\$15.94	12/20/2022	\$11.61	\$13.27
11/8/2022	\$16.42	\$16.10	12/21/2022	\$11.44	\$13.22
11/9/2022	\$14.84	\$15.79	12/22/2022	\$11.67	\$13.17
11/10/2022	\$13.10	\$15.25	12/23/2022	\$11.26	\$13.12
11/11/2022	\$15.34	\$15.26	12/27/2022	\$10.88	\$13.06
11/14/2022	\$14.20	\$15.11	12/28/2022	\$11.09	\$13.00
11/15/2022	\$13.81	\$14.95	12/29/2022	\$11.42	\$12.96
11/16/2022	\$13.64	\$14.80	12/30/2022	\$11.41	\$12.92
11/17/2022	\$14.56	\$14.78	1/3/2023	\$11.10	\$12.88
11/18/2022	\$12.85	\$14.60	1/4/2023	\$11.44	\$12.84
11/21/2022	\$12.46	\$14.43	1/5/2023	\$11.07	\$12.80
11/22/2022	\$12.42	\$14.27	1/6/2023	\$11.24	\$12.76
11/23/2022	\$12.71	\$14.16	1/9/2023	\$11.87	\$12.74
11/25/2022	\$12.79	\$14.07	1/10/2023	\$12.64	\$12.74
11/28/2022	\$12.39	\$13.96	1/11/2023	\$13.68	\$12.76
11/29/2022	\$12.06	\$13.85	1/12/2023	\$13.90	\$12.79
11/30/2022	\$12.95	\$13.80	1/13/2023	\$14.24	\$12.82
12/1/2022	\$13.18	\$13.77	1/17/2023	\$14.19	\$12.84
12/2/2022	\$13.22	\$13.74	1/18/2023	\$14.14	\$12.87
12/5/2022	\$12.53	\$13.68	1/19/2023	\$13.69	\$12.89
12/6/2022	\$13.19	\$13.66	1/20/2023	\$14.33	\$12.91
12/7/2022	\$13.06	\$13.63	1/23/2023	\$15.05	\$12.95
12/8/2022	\$12.71	\$13.60	1/24/2023	\$15.16	\$12.99
12/9/2022	\$12.29	\$13.54	1/25/2023	\$15.03	\$13.03
12/12/2022	\$12.65	\$13.51	1/26/2023	\$15.20	\$13.07
12/13/2022	\$12.57	\$13.47	1/27/2023	\$15.28	\$13.11
12/14/2022	\$12.85	\$13.45	1/30/2023	\$14.65	\$13.14
12/15/2022	\$12.55	\$13.42	1/31/2023	\$14.94	\$13.17
12/16/2022	\$12.42	\$13.39	2/1/2023	\$15.66	\$13.21

HOW ARE CLASS MEMBERS AFFECTED BY THE ACTION AND THE SETTLEMENT?

52. If the Settlement is approved, the Court will enter a judgment (the “Judgment”). The Judgment will dismiss with prejudice the claims against Defendants and will provide that Lead Plaintiffs, and all other Released Plaintiffs Parties (as defined in ¶56 below) shall have waived, released, discharged, and relinquished each and every one of the Released Claims (as defined in ¶53 below), including Unknown Claims (as defined in ¶57 below), against each and every one of the Released Defendants Parties (as defined in ¶55 below) and shall be barred and enjoined from prosecuting any of the Released Claims against any of the Released Defendants Parties, whether or not they execute and deliver the Claim Form or share in the Settlement Fund. Claims to enforce the terms of the Settlement are not released.

53. “Released Claims” means all claims (including, but not limited to, Unknown Claims), demands, losses, rights, and causes of action of any nature whatsoever, that have been or could have been asserted in the Action or could in the future be asserted in any forum, whether foreign or domestic, whether arising under federal, state, common or foreign law, by Plaintiffs, any member of the Class, or their successors, assigns, executors, administrators, representatives, attorneys and agents, whether brought directly or indirectly against any of the Released Defendants Parties, which arise out of, are based on, or relate in any way to, directly or indirectly: (i) any of the allegations, acts, transactions, facts, events, matters, occurrences, representations or omissions involved, set forth, alleged or referred to, in the Action, or which could have been alleged in the Action; and (ii) the purchase or acquisition of CareDx common stock by any member of the Class during the Class Period. For the avoidance of doubt, “Released Claims” does not include claims to enforce the Settlement.

54. “Released Defendants’ Claims” means all claims (including, but not limited to, Unknown Claims), demands, losses, rights, and causes of action of any nature whatsoever, that have been or could have been asserted in the Action by the Released Defendants Parties or any of them against any of the Released Plaintiffs Parties, which arise out of or relate in any way to the institution, prosecution, assertion, settlement, or resolution of the Action (except for claims to enforce the Settlement). Excluded from this definition are any claims by the Released Defendants Parties against Dr. Michael Olymbios, the relator in the action captioned *United States of America, ex. rel. Olymbios v. CareDx, Inc., et al.*, No. 21-CV-00774 (E.D.N.Y.).

55. “Released Defendants Parties” means: (i) each and all of the Defendants; (ii) each of their respective family members (for individuals) and past, present, and future direct and indirect parent entities, subsidiaries, related entities, and affiliates; and (iii) for any of the entities listed in parts (i) and (ii), their respective past and present general partners, limited partners, principals, shareholders, investors (however denominated), joint ventures, members, officers, directors, managers, managing directors, supervisors, employees, contractors, consultants, auditors, accountants, financial advisors, professional advisors, investment bankers, representatives, insurers, trustees, trustors, agents, attorneys, professionals, predecessors, successors, assigns, heirs, executors, administrators, and any controlling person thereof.

56. “Released Plaintiffs Parties” means: (i) each and all of the Plaintiffs and members of the Class; (ii) each of their respective family members, and their respective past, present, and future general partners, limited partners, principals, shareholders, investors (however denominated), joint ventures, members, officers, directors, managers, managing directors, supervisors, employees, contractors, consultants, auditors, accountants, financial advisors, professional advisors, investment bankers, representatives, insurers, trustees, trustors, agents, attorneys, professionals, predecessors, successors, assigns, heirs, executors, administrators, and any controlling person thereof; and (iii) Lead Counsel and other counsel representing Plaintiffs and the Class. Excluded from this definition is Dr. Michael Olymbios, the relator in the action captioned *United States of America, ex. rel. Olymbios v. CareDx, Inc., et al.*, No. 21-CV-00774 (E.D.N.Y.).

57. “Unknown Claims” means any and all Released Claims that Lead Plaintiffs or any other Class Members do not know or suspect to exist in their favor at the time of the release of the Released Defendants Parties, and any and all Released Defendants’ Claims that any Defendant does not know or suspect to exist in his, her or its favor, which if known by him, her, or it, might have affected his, her, or its decision(s) to enter into this Settlement, execute the Stipulation, and agree to all the various releases set forth herein, or might have affected his, her, or its decision(s) not to object to this Settlement or not exclude himself, herself, or itself from the Class. Unknown Claims include, without limitation, those claims in which some or all of the facts composing the claim may be unsuspected, undisclosed, concealed, or hidden. With respect to any and all Released Claims and Released Defendants’ Claims, the Settling Parties stipulate and agree that, upon the Effective Date, Lead Plaintiffs and Class Members (as regards the Released Claims) and the Defendants (as regards the Released Defendants’ Claims) shall expressly waive and relinquish, and each Class Member shall be deemed to have and by operation of law and of the Judgment shall have, expressly waived and relinquished, to the fullest extent permitted by law, any and all provisions, rights, and benefits conferred by California Civil Code §1542, or any law of any state or territory

of the United States, or principle of common law or of international or foreign law, which is similar, comparable, or equivalent to Cal. Civ. Code §1542, which provides:

A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.

The Settling Parties may hereafter discover facts in addition to or different from those which he, she, or it now knows or believes to be true with respect to the subject matter of the Released Claims or Released Defendants' Claims, but such person or entity shall expressly settle and release, and each Member of the Class, upon the Effective Date, shall be deemed to have, and by operation of the Judgment shall have, fully, finally, and forever settled and released any and all Released Claims and Released Defendants' Claims, known or unknown, suspected or unsuspected, contingent or non-contingent, whether or not concealed or hidden, which now exist, or heretofore have existed, upon any theory of law or equity now existing or coming into existence in the future, including, but not limited to, conduct which is negligent, intentional, with or without malice, or a breach of any duty, law or rule, without regard to the subsequent discovery or existence of such different or additional facts. Lead Plaintiffs and Defendants acknowledge and the members of the Class by operation of the Judgment shall be deemed to have acknowledged that the waivers contained in this paragraph, and the inclusion of "Unknown Claims" in the definition of Released Claims and Released Defendants' Claims, were separately bargained for and are material elements of the Settlement.

WHAT PAYMENT ARE THE ATTORNEYS FOR THE CLASS SEEKING? HOW WILL THE LAWYERS BE PAID?

58. Lead Counsel has not received any payment for its services in pursuing claims against Defendants on behalf of the Class, nor has Lead Counsel been paid for its expenses. Before final approval of the Settlement, Lead Counsel intends to apply to the Court for an award of attorneys' fees from the Settlement Fund of no more than 30% of the Settlement Amount, plus interest. At the same time, Lead Counsel also intends to apply for payment from the Settlement Fund for counsel's litigation expenses in a total amount not to exceed \$450,000, plus interest. The Court will determine the amount of the award of fees and expenses. Such sums as may be approved by the Court will be paid from the Settlement Fund. Class Members are not personally liable for any such fees or expenses.

HOW DO I PARTICIPATE IN THE SETTLEMENT? WHAT DO I NEED TO DO?

59. To be eligible for a payment from the proceeds of the Settlement, you must be a member of the Class, and you must timely complete and return the Claim Form with adequate supporting documentation postmarked or submitted online no later than November 12, 2025. You may go to the website maintained by the Claims Administrator for the Settlement to download a Claim Form. The website is www.CareDxSecuritiesLitigation.com. You may also request a Claim Form by calling toll-free 1-877-423-0707. Those who submit a valid and timely request to exclude themselves from the Class, and those who do not submit timely and valid Claim Forms with adequate supporting documentation, will not be entitled to share in the proceeds of the Settlement unless otherwise ordered by the Court. Please retain all original records of your ownership of, or transactions in the shares, as they may be needed to document your claim.

WHAT IF I DO NOT WANT TO BE A MEMBER OF THE CLASS? HOW DO I EXCLUDE MYSELF?

60. To exclude yourself from the Class, you must send a letter by First-Class Mail stating that you "request exclusion from the Class in the *CareDx Securities Litigation*." To be valid, your letter must include the number of shares of CareDx common stock purchased/acquired and sold during the Class Period and the dates and prices of each purchase/acquisition and sale, and the number of shares held at the beginning of the Class Period. In addition, you must include your name, address, telephone number, and your signature. You must submit your exclusion request so that it is **received no later than October 14, 2025** to:

CareDx Securities Litigation
c/o A.B. Data, Ltd.
Claims Administrator
EXCLUSIONS
P.O. Box 173001
Milwaukee, WI 53217

61. A request for exclusion shall not be effective unless it provides all the information called for in this Notice and is received within the time stated above, or is otherwise accepted by the Court. If you ask to be excluded, you will not get any payment from the Settlement, and you cannot object to the Settlement. If you exclude yourself, you may not send in a Claim Form to ask for any money. You will not be legally bound by anything that happens in this lawsuit, and you may be able to sue the Defendants and the other Released Defendants Parties about the Released Claims in the future.

62. Unless you exclude yourself, you give up any rights you may potentially have to sue the Defendants and the other Released Defendants Parties for any and all Released Claims. If you have a pending lawsuit against the Released Defendants Parties, speak to your lawyer in that case immediately. You must exclude yourself from the Class in this Action to continue your own lawsuit. Remember, the exclusion deadline is October 14, 2025.

**WHEN AND WHERE WILL THE COURT DECIDE WHETHER TO APPROVE THE SETTLEMENT?
DO I HAVE TO COME TO THE HEARING?
MAY I SPEAK AT THE HEARING IF I DO NOT LIKE THE SETTLEMENT?**

63. **If you do not wish to object in person to the proposed Settlement, the proposed Plan of Allocation, and/or the application for attorneys' fees and litigation expenses, you do not need to attend the Settlement Hearing. You can object to or participate in the Settlement without attending the Settlement Hearing.**

64. The Settlement Hearing will be held on December 2, 2025, at 2:00 p.m., before the Honorable Trina L. Thompson, at the United States District Court, Northern District of California, Philip Burton Federal Building & United States Courthouse, Courtroom 9 – 19th Floor, 450 Golden Gate Avenue, San Francisco, CA 94102. The Court reserves the right to approve the Settlement or the Plan of Allocation, Lead Counsel's motion for an award of attorneys' fees and expenses, and/or any other matter related to the Settlement at or after the Settlement Hearing without further notice to the members of the Class.

65. Any Class Member who has not submitted a request for exclusion may object to the Settlement, the Plan of Allocation, or Lead Counsel's request for an award of attorneys' fees and litigation expenses.⁴ You can ask the Court to deny approval by filing an objection. You cannot ask the Court to order a different settlement; the Court can only approve or reject the Settlement. If the Court denies approval, no settlement payments will be sent out and the lawsuit will continue. If that is what you want to happen, you must object.

66. Any objection to the proposed Settlement must be in writing. If you file a timely written objection, you may, but are not required to, appear at the Settlement Hearing, either in person or through your own attorney. If you appear through your own attorney, you are responsible for hiring and paying that attorney. All written objections and supporting papers must: (i) clearly identify the case name and number (*Plumbers & Pipefitters Local Union #295 Pension Fund v. CareDx, Inc., et al.*, No. 3:22-cv-03023-TLT (N.D. Cal.)); (ii) be submitted to the Court either by mailing them to the Clerk of the Court, United States District Court for the Northern District of California, 450 Golden Gate Avenue, San Francisco, CA 94102, or by filing them electronically or in person at any location of the United States District Court for the Northern District of California; and (iii) be filed or received on or before October 14, 2025.

67. The notice of objection must include documentation establishing the objecting Person's membership in the Class, including the number of shares of CareDx common stock that the objecting Person: (i) owned as of the opening of trading on May 1, 2020; and (ii) purchased and/or sold during the Class Period, as well as the dates and prices for each such purchase and sale, and contain a statement of reasons for the objection, copies of any papers, briefs, or other documents upon which the objection is based, a statement of whether the objector intends to appear at the Settlement Hearing, and the objector's signature, even if represented by counsel. The objection must state whether it applies only to the objector, to a specific subset of the Class, or to the entire Class. In addition, the objector must identify all class action settlements to which the objector and his, her, or its counsel have previously objected. Documentation establishing membership in the Class must consist of copies of brokerage confirmation slips or monthly brokerage account statements, or an authorized statement from the objector's broker containing the transactional and holding information found in a broker confirmation slip or account statement. Objectors who desire to present evidence at the Settlement Hearing in support of their objection

⁴ Lead Plaintiffs' initial motion papers in support of these matters will be filed with the Court on or before September 30, 2025.

must include in their written objection or notice of appearance the identity of any witnesses they may call to testify and any exhibits they intend to introduce into evidence at the hearing.

68. You may not object to the Settlement or any aspect of it, if you exclude yourself from the Class.

69. You may file a written objection without having to appear at the Settlement Hearing. You may not appear at the Settlement Hearing to present your objection, however, unless you have first filed a written objection in accordance with the procedures described above, unless the Court orders otherwise.

70. You are not required to hire an attorney to represent you in making written objections or in appearing at the Settlement Hearing. If you decide to hire an attorney, which will be at your own expense, he or she must file a notice of appearance with the Court so that the notice is received on or before October 14, 2025.

71. The Settlement Hearing may be adjourned by the Court without further written notice to the Class. Class Members should check the Court's PACER site or the Settlement website, www.CareDxSecuritiesLitigation.com. Any updates regarding the Settlement Hearing, including any changes to the date or time of the hearing, or updates regarding in-person, telephonic, or video conference appearances at the hearing, will be posted to the Settlement website.

Unless the Court orders otherwise, any Class Member who does not object in the manner described above will be deemed to have waived any objection and shall be forever foreclosed from making any objection to the proposed Settlement, the proposed Plan of Allocation, or Lead Counsel's request for an award of attorneys' fees and litigation expenses. Class Members do not need to appear at the hearing or take any other action to indicate their approval.

WHAT IF I BOUGHT SHARES ON SOMEONE ELSE'S BEHALF?

72. If you purchased or otherwise acquired CareDx common stock during the Class Period for the beneficial interest of persons or organizations other than yourself, you must either: (i) request within seven (7) calendar days of receipt of the Postcard Notice sufficient copies of the Postcard Notice from the Claims Administrator to forward to all such beneficial owners; or (ii) send a list of the names and addresses (including email addresses if available) of such beneficial owners to the Claims Administrator within seven (7) calendar days after receipt of the Postcard Notice. If a nominee elects to send the Postcard Notice to beneficial owners, such nominee is directed to email or mail (where an email is unavailable) the Postcard Notice within seven (7) calendar days of receipt of those documents from the Claims Administrator, and upon such emailing or mailing, the nominee shall send a statement to the Claims Administrator confirming that the emailing or mailing was made as directed, and the nominee shall retain the list of names and addresses for use in connection with any possible future notice to the Class. Upon full compliance with these instructions, including the timely emailing or mailing of the Postcard Notice to beneficial owners, such nominees may seek reimbursement of their reasonable expenses actually incurred in complying with these instructions by providing the Claims Administrator with proper documentation supporting the expenses for which reimbursement is sought and reflecting compliance with these instructions, including timely emailing or mailing of the Postcard Notice, if the nominee elected or elects to do so. Reasonable out-of-pocket expenses actually incurred in connection with the foregoing includes up to \$0.03 for providing names, addresses, and email addresses to the Claims Administrator per record; up to a maximum of \$0.03 per Postcard Notice mailed by you, plus postage at the rate used by the Claims Administrator; or \$0.03 per notice sent by email. Such properly documented expenses incurred by nominees in compliance with the terms of these instructions will be paid from the Settlement Fund. Copies of this Notice may also be obtained by calling toll-free 1-877-423-0707, and may be downloaded from the Settlement website, www.CareDxSecuritiesLitigation.com.

**CAN I SEE THE COURT FILE?
WHOM SHOULD I CONTACT IF I HAVE QUESTIONS?**

73. This Notice contains only a summary of the terms of the proposed Settlement. More detailed information about the matters involved in the Action is available at www.CareDxSecuritiesLitigation.com, including, among other documents, copies of the Stipulation and Claim Form. This Notice summarizes the proposed Settlement. For the precise terms and conditions of the Settlement, please see the Stipulation available at www.CareDxSecuritiesLitigation.com, or by contacting the Claims Administrator at info@CareDxSecuritiesLitigation.com. You may also access the Court docket in this case, for a fee, through the Court's Public Access to Court Electronic Records (PACER) system at <https://ecf.cand.uscourts.gov>, or by visiting the office of the Clerk of the Court for the United States District Court for the Northern District of California, 450 Golden Gate Avenue, San Francisco, CA 94102, between 9:00 a.m. and 4:00 p.m., Monday through Friday, excluding Court holidays. All inquiries concerning this Notice or the Claim Form should be directed to:

CareDx Securities Litigation
c/o A.B. Data, Ltd.
Claims Administrator
P.O. Box 173096
Milwaukee, WI 53217
1-877-423-0707

-or-

Jason C. Davis, Esq.
Robbins Geller Rudman & Dowd LLP
Post Montgomery Center
One Montgomery Street, Suite 1800
San Francisco, CA 94104

Lester R. Hooker
Saxena White P.A.
7777 Glades Road, Suite 300
Boca Raton, FL 33434

Lead Counsel

**DO NOT CALL OR WRITE THE COURT, DEFENDANTS, DEFENDANTS' COUNSEL, OR THE
OFFICE OF THE CLERK OF COURT
REGARDING THIS NOTICE.**

Dated: July 23, 2025

By Order of the Court
United States District Court
Northern District of California